Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A.

Although in the NCT01484080 trial patients were randomized 1:1, and thus the main clinical and pathologic characteristics of the patients were well balanced among both treatment arms, the cohort of patients with valid samples was slightly imbalanced (Supplementary Table 1 ): valid tumour samples from patients who received paclitaxel monotherapy ( N = 39) were somehow smaller, with fewer involved axillary nodes, and of lower grade and replicative fraction than those from patients who received the combination treatment ( N = 46); however, these differences did not reach statistical significance.

also in 111,027 other papers

P -values below 0.01 were considered significant, whereas P -values between 0.01 and 0.1 were considered borderline significant.

also in 11,409 other papers